31 Jul 2026 18:00 CEST
EUROAPI S.A.
Press Release
Paris, 31 July 2026
Availability of 2026 Half-Year Financial Report
EUROAPI posted today its 2026 condensed Half Year Consolidated Financial Statements for the six months ended June 30, 2026. This document is available for consultation and downloading on EUROAPI's website: (link is external)2026 Half year results | EUROAPI
This report includes notably the 2026 half-year management report, the consolidated financial statements on 30 June 2026, and the Statutory Auditors' review report on the half-yearly financial information.
About EUROAPI
EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet customers' and patients' needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are committed to building together the future of public health by advancing and securing access to essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on Euronext Paris: EAPI. Find out more at (link is external)www.euroapi.com and follow us on (link is external)LinkedIn.
|
Media Relations contacts: Laurence Bollack Tel.: +33 (0)6 81 86 80 19 (link sends email)mr@euroapi.com Arnaud Jacques Tel. : +33 (0)6 25 64 01 11 (link sends email)arnaud.jacques@teneo.com | Investor Relations contacts: Sophie Palliez-Capian Tel.: +33 (0)6 87 89 33 51 (link sends email)Sophie.palliez@euroapi.com Léa Massonneau Tel: +33 (0)7 60 32 29 50 lea.massonneau@euroapi.com |
Attachment
- (link is external)EUROAPI_Availability of 2026 Half-year results financial report_31JUL26
Euroapi
GlobeNewswire
EUROAPI SA
FR0014008VX5
EAPI
Euronext